PharmAbcine Obtains New Patent Related to EGFRvIII Antibody
[Asia Economy Reporter Minwoo Lee] PharmAbcine announced on the 21st that it has obtained a patent for 'New EGFRvIII Antibody and Compositions Containing the Same.'
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- Signed Without Viewing for 1.6 Billion Won... Jamsil and Seongbuk Jeonse Prices Jump 200 Million Won in a Month [Real Estate AtoZ]
- "Groups of 5 or More Now Restricted"... Unrelenting Running Craze Leaves Citizens and Police Exhausted
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
The company stated, "This patent relates to an antibody that does not cross-react with EGFR but specifically binds to EGFRvIII, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumors containing the antibody as an active ingredient." They explained, "EGFRvIII is a target expressed only in tumors and not in normal cells, and it can be utilized in the development of therapeutics such as antibody-drug conjugates (ADC), CAR-T, CAR-NK, CAR-Macrophage, and bispecific antibodies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
